DISCUSSION
The authors have disclosed no conflicts.
REFERENCES
1. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072.
2. Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27-40.
3. Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43-53.
4. Papp KA, Lebwohl MG. Onset of action of biologics in patients with moderate- to-severe psoriasis. J Drugs Dermatol. 2017;17(3):247-250.
5. Nehring P, Przybylkowski A. Is psoriasis treatment a risk factor for inflammatory bowel disease? Pharmaceut Med. 2020;34(4):257-262.
6. Lebwohl M, Blauvelt A, Paul C, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol. 2018;79(2):266-276 e265.
7. Mariette X, Forger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228-233.
8. Tremfya. Package Insert. Available from: https://www.accessdata.fda.gov/ drugsatfda_docs/label/2020/761061s007lbl.pdf. Cited on: 10/30/2020.
9. Warren RB, Gooderham M, Burge R, et al. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis. J Am Acad Dermatol. 2020;82(5):1138-1149.
10. Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418-431.
11. Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatorcontrolled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405-417.
12. Skyrizi. Package Insert. Available from: https://www.accessdata.fda.gov/ drugsatfda_docs/label/2019/761105s000lbl.pdf. Cited on: 10/30/2020.
13. Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2017;376(16):1551- 1560.
14. Cosentyx. Package Insert. Available from: https://www.accessdata.fda.gov/ drugsatfda_docs/label/2020/125504s035lbl.pdf Cited on 10/30/2020.
15. Reich K, Leonardi C, Langley RG, et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2017;76(3):441-448 e442.
16. Taltz. Package Insert. Available from: https://www.accessdata.fda.gov/drugsatfda_ docs/label/2019/125521s016lbl.pdf Cited on 10/30/2020.
17. Siliq. Package Insert. Available from: https://www.accessdata.fda.gov/drugsatfda_ docs/label/2017/761032lbl.pdf. Cited on: 10/30/2020.
2. Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27-40.
3. Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43-53.
4. Papp KA, Lebwohl MG. Onset of action of biologics in patients with moderate- to-severe psoriasis. J Drugs Dermatol. 2017;17(3):247-250.
5. Nehring P, Przybylkowski A. Is psoriasis treatment a risk factor for inflammatory bowel disease? Pharmaceut Med. 2020;34(4):257-262.
6. Lebwohl M, Blauvelt A, Paul C, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol. 2018;79(2):266-276 e265.
7. Mariette X, Forger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228-233.
8. Tremfya. Package Insert. Available from: https://www.accessdata.fda.gov/ drugsatfda_docs/label/2020/761061s007lbl.pdf. Cited on: 10/30/2020.
9. Warren RB, Gooderham M, Burge R, et al. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis. J Am Acad Dermatol. 2020;82(5):1138-1149.
10. Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418-431.
11. Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatorcontrolled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405-417.
12. Skyrizi. Package Insert. Available from: https://www.accessdata.fda.gov/ drugsatfda_docs/label/2019/761105s000lbl.pdf. Cited on: 10/30/2020.
13. Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2017;376(16):1551- 1560.
14. Cosentyx. Package Insert. Available from: https://www.accessdata.fda.gov/ drugsatfda_docs/label/2020/125504s035lbl.pdf Cited on 10/30/2020.
15. Reich K, Leonardi C, Langley RG, et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2017;76(3):441-448 e442.
16. Taltz. Package Insert. Available from: https://www.accessdata.fda.gov/drugsatfda_ docs/label/2019/125521s016lbl.pdf Cited on 10/30/2020.
17. Siliq. Package Insert. Available from: https://www.accessdata.fda.gov/drugsatfda_ docs/label/2017/761032lbl.pdf. Cited on: 10/30/2020.
AUTHOR CORRESPONDENCE
Amena Alkeswani MD aalkeswa@uthsc.edu
